🔗 Share this article

Given that the US undertakes historic adjustments to its vaccination schedules, a particular individual has emerged unexpectedly: Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by questioning Covid shots in the pandemic and has concentrated on alleged fatalities following COVID-19 vaccination in her recent tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Immunization Schedule

Agency leaders had intended to announce sweeping changes to the pediatric vaccination calendar earlier this month, aligning the US with the Danish vaccine program, according to reports – a substantial departure that would place the US out of step with much of the world with no evidence for improved outcomes. This reveal has been postponed until the next year.

Rather than Vinay Prasad, Høeg is set to speak at the event. She was recently named acting director of the FDA’s CDER, the fifth person to lead the center this calendar year.

A New Direction at the Regulatory Body

This interim role may indicate a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for ending some childhood vaccine recommendations in the US to become more like Denmark, a country with comprehensive healthcare and a citizenry approximately the size of the state of Wisconsin.

So far statements, she has continued to focus on vaccination policy – usually the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Background

The appointee has no apparent track record in pharmaceutical research, oversight or leadership, which has been typical for past leaders of the biologics center. She has served at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in managing a sizeable institution. She lacks background in drug approvals.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of drug development”, commented Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who led the center have had.”

CDER has an vast workload at the FDA, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the generic program authorizes thousands of generic medications. There’s a biologic copycat branch, non-prescription drug unit and more, and all of those need to be managed,” Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial management element to the position, which manages in excess of 5,000 employees. “It is a enormous management job, if you do it right,” Woodcock concluded.

Official Statement and Disputed Initiatives

In response to concerns about Dr. Høeg's qualifications and whether this appointment signifies more teamwork among agency officials on immunizations, a representative responded that the “questions rely on incorrect premises”.

“Her experience is consistent with the duties of her position,” the official explained, noting the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a disputed expedited drug-approval program that allegedly concerned her former heads. “By what process are these therapies being selected for this fast-track system? Who makes the choices?” Dr. Howard said. “There’s a lot of lack of transparency going on at the regulatory body right now.”

Overall, he stated, “the agency looks to be trending towards less stringent regulations of most medications, except for immunizations.”

Public History on Immunizations

Concerning immunizations, Høeg has a clearer, if concerning, history, some experts observe. She authored a research paper using unconfirmed volunteer-provided data to determine the incidence of heart inflammation after COVID-19 vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the current federal leadership encompassed altering rules for recently developed shots and ending “unnecessary” immunizations, she said following the vote on a online show. At the agency, Dr. Høeg has according to sources proposed barring adolescent males from getting COVID-19 vaccinations.

“She’s an complete ideologue who commences with her beliefs and tailors the evidence to fit the data in a very disingenuous, dishonest way,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg joined fellow skeptics, {like|